Lamond David's Form 4 filing
Quince Therapeutics, Inc. (QNCX) · filed Aug 17, 2023
- Accession no.
- 0001209191-23-046402
- Filed
- Aug 17, 2023
- Trade date
- Aug 15-17, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $325.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lamond DavidCIK 0001770790 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2023 | Common Stock | PPurchaseAcquired | +107,886 | $1.32 | +$142,409.52 | 1,954,995 | Indirect | |
| Aug 16, 2023 | Common Stock | PPurchaseAcquired | +117,348 | $1.29 | +$151,378.92 | 2,072,343 | Indirect | |
| Aug 17, 2023 | Common Stock | PPurchaseAcquired | +24,766 | $1.29 | +$31,948.14 | 2,097,109 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.